In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes
WM Kast, CJM Melief - Immunology letters, 1991 - Elsevier
The in vivo efficacy of virus-and tumor-specific cytotoxic T lymphocytes (CTL) is discussed as
well as ways to activate these cells in vivo with lymphokines, monoclonal antibodies and
immunization. In vivo and in vitro peptide immunization can induce such virus-and tumor-
specific CTL but several questions have to be answered before peptide vaccination can be
implemented as a novel immunotherapeutic or preventive approach in man.
well as ways to activate these cells in vivo with lymphokines, monoclonal antibodies and
immunization. In vivo and in vitro peptide immunization can induce such virus-and tumor-
specific CTL but several questions have to be answered before peptide vaccination can be
implemented as a novel immunotherapeutic or preventive approach in man.
